239 related articles for article (PubMed ID: 36114130)
1. Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G.
Stanfield BA; Bravo FJ; Dixon DA; Chouljenko VN; Kousoulas KG; Bernstein DI
Vaccine; 2022 Oct; 40(42):6093-6099. PubMed ID: 36114130
[TBL] [Abstract][Full Text] [Related]
2. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.
Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG
Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955
[TBL] [Abstract][Full Text] [Related]
3. Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials.
Bernstein DI; Cardin RD; Pullum DA; Bravo FJ; Kousoulas KG; Dixon DA
PLoS One; 2019; 14(3):e0213401. PubMed ID: 30917165
[TBL] [Abstract][Full Text] [Related]
4. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.
Awasthi S; Zumbrun EE; Si H; Wang F; Shaw CE; Cai M; Lubinski JM; Barrett SM; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
J Virol; 2012 Apr; 86(8):4586-98. PubMed ID: 22318147
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
6. Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.
Bernstein DI; Cardin RD; Bravo FJ; Hamouda T; Pullum DA; Cohen G; Bitko V; Fattom A
Vaccine; 2019 Oct; 37(43):6470-6477. PubMed ID: 31515143
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4
Srivastava R; Roy S; Coulon PG; Vahed H; Prakash S; Dhanushkodi N; Kim GJ; Fouladi MA; Campo J; Teng AA; Liang X; Schaefer H; BenMohamed L
J Virol; 2019 May; 93(9):. PubMed ID: 30787156
[TBL] [Abstract][Full Text] [Related]
8. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
[TBL] [Abstract][Full Text] [Related]
9. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.
Hoshino Y; Pesnicak L; Dowdell KC; Burbelo PD; Knipe DM; Straus SE; Cohen JI
J Infect Dis; 2009 Oct; 200(7):1088-95. PubMed ID: 19702506
[TBL] [Abstract][Full Text] [Related]
10. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
Awasthi S; Huang J; Shaw C; Friedman HM
J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
[TBL] [Abstract][Full Text] [Related]
12. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
Wang K; Goodman KN; Li DY; Raffeld M; Chavez M; Cohen JI
J Virol; 2016 Jan; 90(1):562-74. PubMed ID: 26559846
[TBL] [Abstract][Full Text] [Related]
13. Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses.
Stanfield BA; Rider PJF; Caskey J; Del Piero F; Kousoulas KG
Vaccine; 2018 May; 36(20):2842-2849. PubMed ID: 29655629
[TBL] [Abstract][Full Text] [Related]
14. A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.
Stanfield BA; Stahl J; Chouljenko VN; Subramanian R; Charles AS; Saied AA; Walker JD; Kousoulas KG
PLoS One; 2014; 9(10):e109890. PubMed ID: 25350288
[TBL] [Abstract][Full Text] [Related]
15. Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses.
Stanfield BA; Kousoulas KG; Fernandez A; Gershburg E
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452501
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE
J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834
[TBL] [Abstract][Full Text] [Related]
18. Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig.
Bernstein DI; Earwood JD; Bravo FJ; Cohen GH; Eisenberg RJ; Clark JR; Fairman J; Cardin RD
Vaccine; 2011 Mar; 29(11):2071-8. PubMed ID: 21238569
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral local tissue-resident and effector memory CD4
Quadiri A; Prakash S; Dhanushkodi NR; Singer M; Zayou L; Shaik AM; Sun M; Suzer B; Lau LSL; Chilukurri A; Vahed H; Schaefer H; BenMohamed L
J Virol; 2024 May; 98(5):e0159623. PubMed ID: 38587378
[TBL] [Abstract][Full Text] [Related]
20. A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigs.
Zhang P; Xie L; Balliet JW; Casimiro DR; Yao F
PLoS One; 2014; 9(6):e101373. PubMed ID: 24979708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]